Cytarabine
Cytarabine 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Autologous Stem Cell Transplant、Classic Hodgkin Lymphoma、Acute Myeloid Leukemia With Gene Mutations、Acute Myeloid Leukemia (AML)。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
4 项
已进入 III/IV 期
17 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Masonic Cancer Center, University of Minnesota
- PETHEMA Foundation
- The Methodist Hospital Research Institute
- National Cancer Institute (NCI)
- Stichting Hemato-Oncologie voor Volwassenen Nederland
- Kura Oncology, Inc.
- Institute of Hematology & Blood Diseases Hospital, China
- Ascentage Pharma Group Inc.
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、中国、澳大利亚、加拿大、新西兰、Puerto Rico、意大利、西班牙、法国、Argentina、奥地利、比利时
正在招募患者的 Cytarabine 研究
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
I 期招募中美国NCT05735184Intermediate-dose HAD Regimen for CEBPA Double-mutated AML
不适用招募中中国NCT06529250A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.
I 期招募中中国NCT04275518Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
III 期招募中美国澳大利亚加拿大新西兰NCT03959085A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML
I 期 / II 期招募中中国NCT05133882BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
II 期招募中美国NCT06854003CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
II 期招募中美国NCT04493164A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
II 期招募中美国NCT05365035Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML
III 期招募中意大利NCT04168502A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML
不适用招募中中国NCT06329999Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
I 期招募中美国NCT04659616CAV Regimen for R/R AML
II 期招募中中国NCT05657639Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT
II 期 / III 期招募中中国NCT03793517Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation
II 期招募中中国NCT06316960SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
I 期 / II 期招募中中国NCT07153068Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML
II 期招募中中国NCT06221683Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML/HR-MDS and in Combination With Azacitidine in Previously Untreated HR-MDS
I 期招募中美国西班牙NCT06533761Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
I 期 / II 期招募中美国NCT04047641Venetoclax Basket Trial for High Risk Hematologic Malignancies
I 期招募中美国NCT05292664A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients
II 期招募中中国NCT06928376Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine or CPX-351) in Patients of 60 Years Old or More With Adverse Risk Acute Myeloblastic Leukemia (AML) (DARALAM)
I 期招募中法国NCT05749276Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
III 期招募中美国Argentina澳大利亚奥地利NCT07211958Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
II 期招募中美国NCT03418038A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
I 期招募中美国NCT05886049
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。